HIV-infected patients in the African country of Tanzania were more likely to stop taking their medications and to fail treatment if they had to pay for the drugs themselves.
Since 2000, the rates of HIV testing have remained relatively low and constant in the United States, with about one third of Americans ever having had an HIV test, and less than a quarter of the people considered at high risk for contracting the virus that causes AIDS report having been tested in the past year.
The Human Vaccine Institute at Duke University Medical Center has been awarded a $7.6 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) to expand its efforts to standardize and improve the quality
of a crucial blood test used in the treatment of millions of HIV patients worldwide.
Duke University will receive $35 million from billionaire real estate developer David H. Murdock to support a massive biomedical research project at the North Carolina Research Campus (NCRC) in Kannapolis, N.C., university president Richard H. Brodhead, Ph.D., and Chancellor for Health Affairs Victor J. Dzau, M.D., announced Monday.
A study examining whether treatment of herpes simplex virus-2 (HSV-2) lowers risk of becoming HIV-infected among women in Tanzania resulted in no difference in HIV infections. But did the trial take into account the issues of adherence to treatment that may have skewed results? Male circumcision may reduce transmission of some sexually transmitted infections, including HIV, but does this knowledge raise the chances that a circumcised man will increase risky sexual behavior?
By Jeffrey Moe, PhD… In 2002 Henry Grabowski, David Ridley, and I were awarded a grant to consider the dilemma of “neglected diseases.”
Part 2 in a series on global health. By Anthony So. In the late 1990s, one of my early missions for The Rockefeller Foundation took me to Khayelitsha, a poor township in South Africa. Its corrugated iron shacks stood in sharp contrast to the waterfront of neighboring Cape Town.
An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS. The researchers expect the new findings to aid the search for an HIV vaccine that would work by boosting the protective effects of one or more of these genes, and help the body’s own immune system overcome an infection. It took the international genetics team, called EuroCHAVI, pooling their cohorts of carefully selected patients and using the latest in genome-wide screening technology, 18 months to discover the three genes, that together greatly increase our knowledge of why patients differ in how well they can control the virus that causes AIDS.